BCL11B

Across TCGA pan-cancer cohorts, BCL11B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BCL11B data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BCL11B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BCL11B expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where BCL11B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.921	0.791	.005	31	view →
CCRCC	OS	Median	IV	0.109	0.789	.014	21	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BCL11B–PDAC (OS)

Open the PDAC breakdown →